We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Rescinds Par's ANDA Approval for Zofran ODT
FDA Rescinds Par's ANDA Approval for Zofran ODT
December 13, 2005
The FDA has rescinded approval of Par Pharmaceutical's abbreviated new drug application (ANDA) for a generic version of GlaxoSmithKline's (GSK) anti-nausea treatment Zofran ODT.